1. Scrip
  2. >>New Products

AstraZeneca/Merck’s Lynparza Is First Adjuvant Option For BRCA-Positive Breast Cancer

 
• By Joseph Haas

One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.

Pink flag
AstraZeneca plants flag with first adjuvant option for BRCA+ breast cancer • Source: Alamy

AstraZeneca PLC and partner Merck & Co., Inc. have added a first-in-class indication to PARP inhibitor Lynparza’s (olaparib) US label, making the drug the first approved adjuvant therapy for early, high-risk breast cancer patients with BRCA mutations.

One of two PARP inhibitors approved in breast cancer – along with Pfizer Inc.’s Talzenna (talazoparib) – Lynparza is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 
• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.